75.27USD-3.19%Mkt Cap: 6.69B $P/E: 442.761d ago
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPI…
Industry Peers
Drug Manufacturers - Specialty & GenericIndicators:|
Key Statistics
Company
Market Cap6.69B $
Enterprise Value6.66B $
Revenue (TTM)288.06M $
Gross Profit145.08M $
Net Income (TTM)-68.92M $
Revenue/Share3.320 USD
Last Price75.27 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees216
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)442.76
P/E (Forward)13.51
PEG—
EV/EBITDA142.74
EV/Revenue23.10
P/S23.24
P/B61.20
EPS (TTM)0.17
EPS (Forward)5.57
52W Range
14.0490% of range82.25
52W High82.25 USD
52W Low14.04 USD
Profitability
Gross Margin91.64%
Oper. Margin46.29%
EBITDA Margin16.19%
Profit Margin-43.53%
ROE-154.03%
ROA-21.02%
Growth
Revenue Growth4158.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-35.69M $
CapEx (TTM)6.34M $
FCF Margin3.33%
FCF Yield0.14%
Net Debt-37.96M $
Net Debt/EBITDA-0.81
Balance Sheet
Debt/Equity4.42
Current Ratio2.22
Quick Ratio1.98
Book Value/Sh1.230 USD
Cash/Share2.505 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)74.25 USD
Upside (mean)-1.4%
Target Range60.00 USD – 109.00 USD
$60.00-1.4% to mean$109.00
# Analysts8
Ownership
Shares Out.88.93M
Float62.45M
Insiders12.66%
Institutions70.62%
Short Interest
Short Ratio4.8d
Short % Float18.41%
Short % Out.14.82%
Shares Short13.18M
Short (prev mo.)9.96M
Technical
SMA 5065.28 (+15.3%)
SMA 20041.29 (+82.3%)
Beta0.55
S&P 52W Chg20.25%
Avg Vol (30d)2.16M
Avg Vol (10d)1.36M
Technical Indicators
RSI (14)54.1
MACD3.3955
MACD Signal4.5019
MACD Hist.-1.1064
BB Upper83.81 USD
BB Middle76.08 USD
BB Lower68.34 USD
BB Width20.33%
ATR (14)4.557 USD
Vol Ratio (20d)0.57x